Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
Status:
Unknown status
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to investigate if daily treatment with celecoxib, an
inhibitor of cyclooxygenase-2, can prolong survival in patients with advanced non-small cell
lung cancer who receive anticancer chemotherapy as their primary treatment. Secondary
endpoints of the study are: health-related quality of life, toxicity, cardiovascular events,
progression-free survival, and biological markers (VEGF, proteomics).